• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Ytracis
    / Isotopia


    Active Ingredient
    Yttrium Chloride 1850 MBQ

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Vial

    1 X 2 ml

    partial basket chart

    Dosage

    YTRACIS is only to be used by specialists with the appropriate experience.
    The quantity of YTRACIS required for radiolabelling and the quantity of Yttrium (90Y)-labelled medicinal product that is subsequently administered will depend on the medicinal product radiolabelled and its intended use. Refer to the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled.
    Method of administration: YTRACIS is intended for in vitro radiolabelling of medicinal products, which are subsequently administered by approved route.


    Indications

    To be used only for the radiolabelling of carrier molecules which have been specifically developed and authorized for radiolabelling with Zevalin. Radiopharmaceutical precursor – Not intended for direct application to patients.


    Contra-Indications

    Do not administer directly to the patient. Hypersensitivity to the Yttrium (90Y) chloride or to any of the excipients. Established or suspected pregnancy or when pregnancy has not been excluded.


    Special Precautions

    The content of the vial is not to be administered directly to the patient but must be used for the radiolabelling of Zevalin. See literature.


    Side Effects

    Possible side effects will be dependent on the specific medicdbinal product being used. See prescribing information of the medicdbinal product to be radiolabelled. The radiation dose resulting from therapeutic exposure may result in higher incidence of cancer and mutations. See literature.


    Drug interactions

    See literature.


    Manufacturer
    CIS BIO International
    CLOSE